统计模型结合观察数据预测阿根廷门多萨省儿童甲型肝炎疫苗一剂与两剂接种方案的长期免疫原性
在阿根廷门多萨省实施甲型肝炎病毒(HAV)普遍接种后,对一剂(N=436)或两剂(N=108)HAV疫苗常规接种者随访抗HA抗体持久性至10年,并基于贝叶斯混合效应模型预测至30年。分段线性模型拟合最佳,预测30年血清保护率一剂方案为89%、两剂方案为85%,两剂方案几何平均浓度(GMC)在各时间点均高于一剂方案。自然强化对一剂方案30年血清保护率预测影响有限。
要点
- 10年随访时,未接种加强针的一剂组190人和两剂组51人均保持血清保护。
- 分段线性模型预测30年血清保护率:一剂方案89%,两剂方案85%。
- 第10年GMC两剂组352 mIU/mL高于一剂组78 mIU/mL,第30年预测值分别为37和19 mIU/mL。
核心结论
- 一剂和两剂HAV疫苗方案在10年内均观察到抗HAV抗体持久存在,支持加强针灵活性。
- 统计模型预测两种方案至30年均具有良好的血清保护持久性。
- 自然强化对血清保护率预测影响有限,可将结果外推至非流行区旅行者接种。
研究设计与样本
- 非干预性研究,评估常规接种1剂(Group 1:N=436)或2剂(Group 2:N=108)HAV疫苗后的长期免疫原性(GMC和血清保护率)。
- 基于对数转换滴度的贝叶斯混合效应模型,评估线性、分段线性和指数衰减三种模型(含或不含自然强化效应)。
主要发现
- 初始队列中,Group 1有9人、Group 2有1人抗体滴度低于血清保护阈值并接受了加强针。
- 第10年,Group 1有190人、Group 2有51人未接种加强针仍留在研究中,且全部保持血清保护。
- 分段线性模型拟合最佳,预测30年血清保护率:一剂方案89%,两剂方案85%。
- 第10年GMC(95%CI):两剂方案352(271-456)mIU/mL vs 一剂方案78(69.8-87.6)mIU/mL。
- 第30年预测GMC(95%CI):两剂方案37(13-97)mIU/mL vs 一剂方案19(11-34)mIU/mL。
关键数值与推荐
- 自然强化对一剂方案30年预测血清保护率影响有限:有自然强化89%(0.8-0.96),无自然强化84%(0.73-0.94)。
临床怎么用
- 作者认为,一剂和两剂方案10年抗体持久性支持加强针灵活性。
- 作者认为,自然强化影响有限使预测结果可外推至非流行区旅行者接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Follow-up for anti-hepatitis A (HA) antibody persistence up to 10 years was conducted after implementation of universal vaccination against HA virus (HAV) in Mendoza, Argentina. Based on these data, statistical modeling was used to predict the antibody persistence to 30 years. METHODS: A non-interventional study evaluated long-term immunogenicity (geometric mean concentrations [GMCs] and seroprotection rate) following routine vaccination with 1 dose (Group 1: N = 436) or 2 doses (Group 2: N = 108) of HA vaccine. Associated statistical modeling based on a Bayesian approach of mixed effects models on log transformed titers evaluated three models (linear, piecewise linear, and exponential decay, with and without a natural boosting effect). RESULTS: From the initial cohort, 9 participants (Group 1) and 1 participant (Group 2) showed antibody titers below the seroprotective threshold and received a booster. At Year 10, 190 (Group 1) and 51 (Group 2) participants remained in the study without a booster dose and all were seroprotected. Regarding statistical modeling, the piecewise linear model showed the best fit and demonstrated high and similar seroprotection for each schedule up to 30 years (89% [1-dose schedule], 85% [2-dose schedule]). The 2-dose schedule showed higher GMC (95% CI) than the 1-dose schedule (Year 10: 352 [271-456] versus 78 [69.8-87.6] mIU/mL) and Year 30 (predicted) (37 [13-97] versus 19 [11-34] mIU/mL). Natural boosting had little impact on predicted seroprotection rates at 30 years for the 1-dose schedule (89% [0.8-0.96] and 84% [0.73-0.94] with and without a natural booster, respectively). CONCLUSIONS: Long-term persistence of anti-HAV antibodies was observed up to 10 years with 1-dose and 2-dose vaccine schedules, supporting booster flexibility. Statistical modeling predicted good persistence of seroprotection for each schedule up to 30 years. Natural boosting had a limited impact on seroprotection rate predictions, enabling extrapolation of these results to non-endemic settings for traveler vaccination.
引用
- Espul C, Cuello H, Lo Castro I, et al. Statistical modeling alongside observational data predicts long-term immunogenicity of one dose and two doses of pediatric hepatitis A vaccine in the Mendoza province of Argentina. Vaccine. 2020. PMID: 31928855. doi:10.1016/j.vaccine.2019.12.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。